VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections

H Turley, M Jones, W Erber, K Mayne, M de Waele, K Gatter

Abstract
Aims—To characterise a new mouse monoclonal antibody, VS38, which recognises an intracytoplasmic antigen of 64 kilodaltons present in normal and neoplastic plasma cells; and to establish its value as a diagnostic reagent for routine pathological practice.

Methods—A range of normal and neoplastic tissue sections, both frozen and routinely fixed, were immunostained, using the microwave method of antigen retrieval for routinely fixed specimens. The antibody was also tested on blood and bone marrow specimens and a range of human cell lines. The molecular weight of the antigen recognised by the antibody was obtained by western blot analysis. FACS analysis was used to demonstrate the cellular location of the antigen and its presence on tonsill cell suspensions and myeloma cases.

Results—VS38 recognised normal and neoplastic plasma cells in all of the tissues, including all routinely fixed plasma cell neoplasms tested. The antibody also weakly stained epithelial elements within the tissue but was absent from haemopoietic cells of other lineages.

Conclusion—Antibody VS38 is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It differentiates lymphoplasmacytoid lymphoma from lymphocytic and follicular lymphoma. It also subdivides large cell lymphomas into two groups which may be a more reliable method of separating these tumours than morphology alone.

(J Clin Pathol 1994;47:418–422)

The terminal stage of B cell differentiation is the plasma cell for which no unique antigens have yet been described. Apart from their morphology, plasma cells are usually distinguished from other B cells by their lack of surface HLA class I and class II antigens, surface immunoglobulin, Fc and C3 receptors, and the presence of intracytoplasmic immunoglobulin.1 Most antibodies which stain plasma cells label other B cells as well as cells of other lineages.2-4 Most do not work on routinely fixed material, thus further limiting their usefulness to pathologists.

We describe the characterisation of a mouse monoclonal antibody, VS38, that is reactive with an antigen expressed strongly on normal and neoplastic plasma cells but is absent from haemopoietic cells of other lineages. This antigen is also expressed to some extent in both normal and neoplastic epithelial cells. VS38 was tested on a wide range of normal and neoplastic tissues including solid tumours as well as blood and bone marrow specimens, with the aim of establishing its value as a diagnostic reagent for pathological practice.

Methods
PRODUCTION OF ANTIBODY VS38

The source of antigen was a membrane preparation of MCF-7 AdR cells. About 4 × 10⁶ cells were injected intraperitoneally into a Balb/c mouse, together with Freund’s complete adjuvant. Eleven days later, the mouse was given a booster injection of 1 × 10⁶ cells, with non-complete adjuvant. The booster was repeated again seven days later. Three days after the last injection the mouse was killed and the spleen removed. Cell suspensions were prepared from the spleen and were fused with cells from the myeloma cell line NS1s, using polyethylene glycol to induce cell fusion, as described by Mason and colleagues.7

BIOCHEMICAL ANALYSIS OF THE VS38 EPITOPE

Cell cultures were washed twice with phosphate buffered saline (PBS) and then harvested with 0·25% trypsin and 0·02% EDTA. The cell suspension was washed in culture medium and centrifuged for five minutes at 1000 rpm and 4°C. The cells were washed twice in PBS and centrifuged for a final spin at 2000 rpm for 10 minutes at 4°C. The cell pellet was solubilised with an equal volume of 1% (w/v) Triton X-100 (Sigma) in 10 mM TRIS-HCL (pH 8) for 20 minutes on ice. This was then spun at 2000 rpm for 15 minutes at 4°C and the supernatant fluid collected. This was either used immediately for analysis by polyacrylamide gel electrophoresis (PAGE), or stored as a membrane extract at − 70°C.

SDS-PAGE

Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis was performed on the extract, according to the method of Laemmli.8 Samples were suspended in buffer containing DL-dithiothreitol (Sigma) and boiled for two minutes, allowed to cool, and
loaded on to a gel (5-5% stacking gel, 6-5% running gel). Molecular weight markers (Sigma UK) were run at the same time.

Proteins were transferred electrophoretically using a Transblot (Biorad UK) apparatus to nitrocellulose membranes and the protein detected by applying the antibody, followed by a rabbit-anti-mouse peroxidase conjugate (Dako UK) and visualised using diaminobenzidine with metal ion enhancement.

TISSUES
A representative range of normal and neoplastic tissues, including bone marrow biopsy specimens, was obtained from the Histopathology Department at the John Radcliffe Hospital. Tissues were immediately snap frozen in liquid nitrogen and stored at −70°C. Cryostat sections (5–8 μm) were then cut and collected on to glass multiwell slides and dried overnight at room temperature. The slides were then fixed in acetone at room temperature. The sections were either stained immediately or stored wrapped in aluminium foil at −20°C until staining. Formalin fixed, paraffin wax embedded sections were cut at approximately 5 μm and floated on to silane coated glass slides. These were dewaxed, rehydrated, and microwaved in a 700 Watt microwave for 8 minutes in 0-01 M sodium citrate, then into buffer before staining as normal.

CELL LINES
The following cell lines were obtained from the Sir William Dunn School of Pathology, Oxford: K562 (erythroleukaemia); HeLa (cervical epithelial carcinoma); U937 (malignant histiocytosis); HL60 (promyelocytic leukaemia); RVIH421 (melanoma); A431 (vulval carcinoma); Daudi and Raji (Burkit’s lymphoma); Nalm-1 (pre-B cell leukaemia); and Jurkat (T cell lymphoma). The cell lines L428 (Hodgkin’s disease) and Thiel (plasma cell) were obtained from Dr V Diehl; SU-DHL-1 (T cell leukaemia) from Dr ML Cleary; Karpas 299 (T cell lymphoma with a 2-5 translocation) and Karpas M (plasma cell) from Dr A Karpas; and HT29 (colon carcinoma), MCF 7 ADR (breast carcinoma) from the Imperial Cancer Research Fund, London. The plasma cell lines L363, JNN3, Karpas 707, OPM-1, and EJM were obtained from Professor K Nilsson, University of Upsala, Sweden. LB 84–4 (plasma cell), ARH 77 (plasma cell), and 8226 R10 (plasma cell) were from Professor Brian GM Durie. All cell lines were cultured in RPMI containing 10% fetal calf serum (Gibco Biocult Ltd) at 37°C. Cytocentrifuge preparations were made using a Shandon cytocentrifuge. These were allowed to air dry for at least two hours, then fixed for 10 minutes in acetone.

BLOOD AND BONE MARROW SAMPLES
Samples were obtained from the Haematology Department of the John Radcliffe Hospital and cytopsins were prepared and allowed to dry at room temperature overnight. The slides were then fixed in acetone/methanol (1 in 1) for 60 seconds at room temperature, placed into TBS (0-5M TRIS, pH7-6, diluted 1 in 10 in 0-15M saline) and either stained using the alkaline phosphatase-antialkaline phosphatase (APAAP) technique, or stored wrapped in aluminium foil at −20°C until required. They were then allowed to reach room temperature before fixation, as described.

IMMUNOCYTOCHEMICAL STAINING
The APAAP staining technique was performed, as described before. The enzyme reaction was developed using naphthol-AS-MX-phosphate and fast red (TR-Salt, Sigma Chemical Co) as substrate. For immunoperoxidase labelling tissue sections were incubated first with the monoclonal antibody for 30 minutes, then with peroxidase conjugated rabbit-anti-mouse (Dakopatts), and finally with peroxidase conjugated swine-anti-rabbit immunoglobulin. The peroxidase reaction was developed using diaminobenzidine (Sigma Chemical Co). The slides were then washed and mounted in aqueous mountant (Apathy’s; BDH Poole, Dorset).

FACS ANALYSIS
White cells and mononuclear cells were isolated from peripheral blood and bone marrow aspirates by red cell lysis using ammonium chloride or density centrifugation on Lymphoprep (Nygaard, Oslo). The peripheral blood cells were permeabilised using buffered formol acetone (BFA), as described by Slaper-Cortenbach et al. After washing in phosphate buffered saline (PBS) containing 0-1% bovine serum albumin (BSA), permeabilised cells were incubated for 30 minutes at 4°C with the antibodies. Cells were then washed and incubated for 30 minutes with fluorescein isothiocyanate (FITC) conjugated rabbit-anti-mouse F(ab′)2 immunoglobulin (Dakopatts a/s). After a final wash the cells were fixed in 1-5% formaldehyde in washing buffer and analysed in a FACScan flow cytometer (Becton Dickinson) using Consort 30 and Paint-a-Gate software.

RESULTS

BIOCHEMICAL ANALYSIS OF EPITOPE
A strong band of molecular weight 64 kilodaltons (reduced) was detected by VS38 from extracts of the cell lines Thiel (plasma cell derived), MCF-7, and MCF-7 ADR (breast carcinoma derived) (fig 1). Occasionally a higher molecular weight band of 73 kilodaltons was detected in the MCF-7 ADR cell line (fig 1). No bands could be detected without reducing conditions.

NORMAL TISSUE REACTIVITY
Frozen/fresh material
VS38 was tested on a wide range of normal tissues (table 1). The most striking result is the intense cytoplasmic labelling of all plasma cells (fig 2). All other lymphoid cells were unlabelled. Weak staining of epithelium was detectable in most tissues, and in some cases
Table 1

<table>
<thead>
<tr>
<th>Normal tissue staining of routinely fixed specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonsil</td>
</tr>
<tr>
<td>Gut</td>
</tr>
<tr>
<td>Pancreas</td>
</tr>
<tr>
<td>Lung</td>
</tr>
<tr>
<td>Brain</td>
</tr>
<tr>
<td>Heart</td>
</tr>
<tr>
<td>Cerebellum</td>
</tr>
<tr>
<td>Adrenal</td>
</tr>
<tr>
<td>Kidney</td>
</tr>
<tr>
<td>Spleen</td>
</tr>
</tbody>
</table>

APUD: Amine precursor uptake decarboxylase.

some tissues but were unable to identify these cells.

FACS
Analysis of the tonsil cell suspensions, myeloma cases, and the plasma cell lines with and without permeabilisation showed that the antibody is intracytoplasmic being undetectable without prior permeabilisation (fig 3).

REACTIVITY OF VS38 WITH HUMAN CELL LINES
The antibody reacted with all the plasma cell lines tested. This reactivity was strong and present on all of the cells in the sample. All of the lymphocytic lines were unreactive with VS38 apart from Nalm-1 which showed a weak positivity. Of the myeloid lines tested, only U937 was reactive. The carcinoma lines were also weakly positive in keeping with the tissue staining. The single melanoma cell line examined RVH421 was also positively labelled.

REACTIVITY WITH LYMPHOMAS AND LEUKAEMIAS
The results of staining lymphoma specimens with VS38 are summarised in table 2. All specimens of myeloma and plasmacytoma were strongly labelled (fig 2) as were the lymphoplasmacytoid elements in all of the lymphoplasmacytoid lymphomas. Only in frozen sections was there staining of follicular lymphoma and common lymphocytic leukaemia (CLL). In these cases staining was generally focal and weak (fig 2). There was no staining of T cell lymphomas but 10 of the fixed large B cell lymphomas were positive, albeit much more weakly than the myelomas (fig 2).

Discussion
No plasma cell specific antigens have been described to date, with all of the previously reported antibodies also labelling other cell types, most notably other B cells.3-5 16-18 Two antibodies well known to haematologists, PCA1 and PCA2,16 were reported as being expressed on plasma cells but were also present on granulocytes and monocytes. Other examples more familiar to histopathologists might include antibodies against EMA (epithelial membrane antigen) and CD30 (notably antibody Ber-H2).19-21 Most importantly none of these antibodies has been shown to detect all (or virtually all) plasma cells in formalin fixed material, the main interest of the current study to practising histopathologists. The only antibody other

Table 2 VS38 immunostaining on lymphoma

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Frozen</th>
<th>Paraffin wax</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL</td>
<td>7/13</td>
<td>0/12</td>
</tr>
<tr>
<td>Centroblastic centrocytic lymphoma</td>
<td>2/7</td>
<td>0/6</td>
</tr>
<tr>
<td>Hairy cell leukaemia</td>
<td>0/8</td>
<td>0/4</td>
</tr>
<tr>
<td>Lymphoplasmacytoid lymphoma</td>
<td>2/2</td>
<td>7/7</td>
</tr>
<tr>
<td>B cell large cell non-Hodgkin's lymphoma</td>
<td>0/8</td>
<td>12/38</td>
</tr>
<tr>
<td>T cell non-Hodgkin's lymphoma</td>
<td>NT</td>
<td>0/9</td>
</tr>
<tr>
<td>Myeloma</td>
<td>42/42</td>
<td>7/7</td>
</tr>
<tr>
<td>Plasmacytoma</td>
<td>NT</td>
<td>4/4</td>
</tr>
</tbody>
</table>

Key: NT = not tested. *weak/focal staining.
Plasma cell detection in routine sections

Figure 3  FACS analysis of a bone marrow sample from a case of multiple myeloma. Antibody VS38 shows no surface staining of the neoplastic cells (C). However, following BFA permeabilisation (D), the myeloma cells are labelled by antibody VS38. (A) and (B) show the absence of labelling obtained with antibody Bu20 (negative control) before and after permeabilisation. (SSC = side scatter)

than anti-Ig antibodies described to date, which stains neoplastic plasma cells in fixed sections, is antibody MM4. A drawback of this antibody is that only a subset of the myeloma cells is positive, and this could be a potential problem in small or lightly infiltrated biopsy specimens.

In the current study we have shown that the recently produced antibody VS38 is of potential value in clinical practice. It can be helpful in identifying myeloma or plasmacytoma in bone marrow and other tissues. It also helps to distinguish cases of lymphoplasmacytoid lymphoma from lymphocytic and follicular lymphoma. The only other lymphomas showing positivity were about one third of the cases of large cell non-Hodgkin’s lymphoma. It might be predicted that these would be the immunoblastic rather than the centroblastic or other cell types. However, this is a notoriously difficult area of morphology with very little consensus among pathologists about their identification.

Indeed, a study undertaken by Warnke et al. more than 10 years ago showed that even expert haematopathologists disagreed on the subdivision of large cell lymphomas. They not only disagreed with each other but also with themselves when they re-examined individual cases. This difficulty is reflected in the Kiel classification which makes substantial efforts to define reliably the distinction between immunoblastic and centroblastic lymphoma. In early studies this group believed that immunoblastic was the commonest large cell non-Hodgkin’s lymphoma. This is what the general reader will glean from many textbooks—for example, The Oxford Textbook of Pathology and the first edition of Lymph Node Biopsy Interpretation by Stansfeld. In the second edition of Stansfeld’s book the revised Kiel classification is used and the following explanation is given for centroblastic now being the most common large cell non-Hodgkin’s lymphoma.

"Formerly believed to be the commonest type of high grade large cell lymphoma it is now clear that ML-1B-B (immunoblastic) is less common than centroblastic lymphoma. This reversal is largely due to the inclusion in the ML centroblastic-polyomorphic category of tumours containing a large number of immunoblasts when it can be shown that the tumour is basically of follicular centre cell origin." This undoubtedly reflects difficulty in making the diagnostic subdivision rather than any change in the incidence of the different subtypes of disease.

Separation of these large cell cases on the grounds of reproducible immunostaining, such as that achieved by VS38, may well be a better way of subdividing large cell lymphomas than by morphological examination alone. It is to be hoped that lymphoma groups will incorporate such findings into their study of non-Hodgkin’s lymphomas so that in time a consensus might arise as to whether or not it is useful to subdivide large cell lymphomas and if so on what grounds.

This work was supported in part by the Imperial Cancer Research Fund and the Leukaemia Research Fund.

11 Cattoretti G, Becker MH, Key G, et al. Monoclonal anti-
bodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.


VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections.
H Turley, M Jones, W Erber, K Mayne, M de Waele and K Gatter

J Clin Pathol 1994 47: 418-422
doi: 10.1136/jcp.47.5.418